PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
178.96%
R&D growth 50-75% of TRAW's 297.90%. Bruce Berkowitz would examine spending effectiveness.
203.49%
G&A growth less than half of TRAW's 448.37%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
-29.56%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
185.87%
Operating expenses growth 50-75% of TRAW's 327.04%. Bruce Berkowitz would examine efficiency.
185.87%
Total costs growth 50-75% of TRAW's 327.04%. Bruce Berkowitz would examine efficiency.
-0.66%
Interest expense reduction while TRAW shows 3533.48% growth. Joel Greenblatt would examine advantage.
-29.56%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-185.91%
EBITDA decline while TRAW shows 198.44% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-185.87%
Operating income decline while TRAW shows 184.55% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
15.24%
Other expenses growth while TRAW reduces costs. John Neff would investigate differences.
-92.79%
Pre-tax income decline while TRAW shows 80.65% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-0.66%
Tax expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-92.79%
Net income decline while TRAW shows 80.65% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-3998.91%
EPS decline while TRAW shows 73.39% growth. Joel Greenblatt would examine position.
-3998.91%
Diluted EPS decline while TRAW shows 73.39% growth. Joel Greenblatt would examine position.
-95.29%
Share count reduction while TRAW shows 0.00% change. Joel Greenblatt would examine strategy.
-95.29%
Diluted share reduction while TRAW shows 0.00% change. Joel Greenblatt would examine strategy.